Navigation Links
Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Date:7/23/2008

RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported second quarter 2008 financial results and accomplishments.

For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss of $7.4 million, or $0.18 per share, compared to a net loss of $5.2 million, or $0.15 per share, for the same period in 2007. As of June 30, 2008, the company had cash, cash equivalents and investments of $64.3 million.

Revenues for the second quarter of 2008 were $2.8 million, compared to $2.6 million for the second quarter of 2007. Second quarter 2008 revenues were primarily comprised of revenue recognition from the Company's collaboration agreements with Dow AgroSciences (DAS) and Sigma-Aldrich, enabling technology agreements in protein production and research grants. The revenue recognized for the second quarter of 2008 consisted of $2.4 million in collaboration agreements and $464,000 in research grants.

Research and development expenses were $8.3 million for the second quarter of 2008, compared to $6.3 million for the same period in 2007. The increase in research and development expenses for the second quarter of 2008 was primarily due to advancing the Company's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs. Non-cash employee stock-based compensation included in research and development expenses totaled $0.7 million and $0.3 million in the second quarter of 2008 and 2007, respectively.

General and administrative expenses were $2.5 million for the second quarter of 2008, compared to $2.1 million
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
2. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
3. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
5. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
6. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
7. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
8. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
11. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private guided ... local area veterinarians. , The tour and course will be given every Wednesday at ... VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as well. ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
(Date:7/28/2015)... PARK, N.C., July 28, 2015  United Therapeutics Corporation ... results for the second quarter ended June 30, 2015. ... as compared to the second quarter of 2014 ... Jeffs, Ph.D., United Therapeutics, President and Co-Chief Executive ... to an increase in the number of patients ...
(Date:7/27/2015)... and FRANKLIN, Tenn. , July ... premier provider of health care services and one ... U.S., today announced that its parent company and ... definitive agreement with Medical Properties Trust, Inc. ("MPT") ... Capella for $900 million in cash.  The transaction is expected ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in the discovery ... Dr. Leslie J. Browne,President and Chief Executive Officer, will ... Healthcare Conference hosted by,BMO Capital Markets. The conference will ... in New York City., Dr. Browne,s presentation will ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that ... Piper Jaffray 19th Annual,Health Care Conference at The Pierre ... 2007 at 8:30 a.m. Eastern Time., A live ... website at http://www.lexpharma.com . An archived version of ...
... Archer Daniels Midland,Company (NYSE: ADM ) ... elected to retire by year end., In ... to advance the,Company,s business strategy for Asian investments ... Company,s strategic planning group,under the direction of Steve ...
Cached Biology Technology:Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 2Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 3Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 2ADM Executive Vice President Bill Camp to Retire 2
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Women,s skulls are thicker than men,s, but they both ... of a new imaging study of 3000 people published ... detailed results could help in the design of more ... and other accidents. Jesse Ruan of the Ford ...
... MADISON - The deadly Ebola virus, an emerging public ... ranks among the most feared of exotic pathogens. ... or treatments are available, scientists studying the agent have ... limiting research to a few highly specialized labs and ...
... the University of Exeter has highlighted the problems ... projects. Published online in the journal Biological Conservation, ... captive carnivores that are released into their natural ... carnivores survives in the wild, with most deaths ...
Cached Biology News:Skull survey could improve vehicle safety 2Ebola virus disarmed by excising a single gene 2Ebola virus disarmed by excising a single gene 3Captive carnivores not up to wild living 2
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: